Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
CONNECTED COMPANY
 
My Lists

OSI Pharmaceuticals  (Stock symbol: OSIP )

41 Pinelawn Road
Melville, NY 11747
1-631-9622000
Website Company Summary Management Team
Team

Management: Colin Goddard (CEO)
Business Description

OSI Pharmaceuticals, Inc. (OSI) is a biotechnology company focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, diabetes and obesity. The Company's focus is on oncology and its flagship product is Tarceva (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor (EGFR). OSI also has research and development programs in diabetes and obesity, which are conducted through Prosidion Limited, the Company's United Kingdom subsidiary. Roche Holding Ltd. and OSI announced that Tarceva (erlotinib) has been approved in Japan for the treatment of patients with nonresectable, recurrent and advanced non-small cell lung cancer (NSCLC), which is aggravated following chemotherapy.
Customer on 2  Companies

Last Tweets


 

Last Mentions


Overview
Record updated: Sep 2010
Ownership: Public  
Stock Symbol: OSIP